These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 12782059

  • 1. Rational antibacterial vaccine design through genomic technologies.
    Grandi G.
    Int J Parasitol; 2003 May; 33(5-6):615-20. PubMed ID: 12782059
    [Abstract] [Full Text] [Related]

  • 2. Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens.
    Serruto D, Adu-Bobie J, Capecchi B, Rappuoli R, Pizza M, Masignani V.
    J Biotechnol; 2004 Sep 30; 113(1-3):15-32. PubMed ID: 15380644
    [Abstract] [Full Text] [Related]

  • 3. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
    Bai X, Borrow R.
    Expert Rev Vaccines; 2010 Oct 30; 9(10):1203-17. PubMed ID: 20923270
    [Abstract] [Full Text] [Related]

  • 4. Antibacterial vaccine design using genomics and proteomics.
    Grandi G.
    Trends Biotechnol; 2001 May 30; 19(5):181-8. PubMed ID: 11301131
    [Abstract] [Full Text] [Related]

  • 5. The impact of genomics on vaccine design.
    Scarselli M, Giuliani MM, Adu-Bobie J, Pizza M, Rappuoli R.
    Trends Biotechnol; 2005 Feb 30; 23(2):84-91. PubMed ID: 15661345
    [Abstract] [Full Text] [Related]

  • 6. Developing vaccines in the era of genomics: a decade of reverse vaccinology.
    Seib KL, Zhao X, Rappuoli R.
    Clin Microbiol Infect; 2012 Oct 30; 18 Suppl 5():109-16. PubMed ID: 22882709
    [Abstract] [Full Text] [Related]

  • 7. Genome-based vaccine development: a short cut for the future.
    Moriel DG, Scarselli M, Serino L, Mora M, Rappuoli R, Masignani V.
    Hum Vaccin; 2008 Oct 30; 4(3):184-8. PubMed ID: 20686357
    [Abstract] [Full Text] [Related]

  • 8. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus.
    Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M.
    Vaccine; 2009 May 11; 27(21):2794-803. PubMed ID: 19428890
    [Abstract] [Full Text] [Related]

  • 9. Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis.
    Kelly DF, Rappuoli R.
    Adv Exp Med Biol; 2005 May 11; 568():217-23. PubMed ID: 16107075
    [Abstract] [Full Text] [Related]

  • 10. The promise of reverse vaccinology.
    Heinson AI, Woelk CH, Newell ML.
    Int Health; 2015 Mar 11; 7(2):85-9. PubMed ID: 25733557
    [Abstract] [Full Text] [Related]

  • 11. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays.
    Grifantini R, Bartolini E, Muzzi A, Draghi M, Frigimelica E, Berger J, Ratti G, Petracca R, Galli G, Agnusdei M, Giuliani MM, Santini L, Brunelli B, Tettelin H, Rappuoli R, Randazzo F, Grandi G.
    Nat Biotechnol; 2002 Sep 11; 20(9):914-21. PubMed ID: 12172557
    [Abstract] [Full Text] [Related]

  • 12. Reverse vaccinology--in search of a genome-derived meningococcal vaccine.
    Danzig L.
    Vaccine; 2006 Apr 12; 24 Suppl 2():S2-11-2. PubMed ID: 16823908
    [Abstract] [Full Text] [Related]

  • 13. Identification of new potential vaccine candidates against Chlamydia pneumoniae by multiple screenings.
    Finco O, Bonci A, Agnusdei M, Scarselli M, Petracca R, Norais N, Ferrari G, Garaguso I, Donati M, Sambri V, Cevenini R, Ratti G, Grandi G.
    Vaccine; 2005 Jan 19; 23(9):1178-88. PubMed ID: 15629361
    [Abstract] [Full Text] [Related]

  • 14. Genome-based bacterial vaccines: current state and future outlook.
    Schubert-Unkmeir A, Christodoulides M.
    BioDrugs; 2013 Oct 19; 27(5):419-30. PubMed ID: 23588477
    [Abstract] [Full Text] [Related]

  • 15. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
    Holst J.
    Hum Vaccin; 2007 Oct 19; 3(6):290-4. PubMed ID: 17712231
    [Abstract] [Full Text] [Related]

  • 16. Developing antibacterial vaccines in genomics and proteomics era.
    Kaushik DK, Sehgal D.
    Scand J Immunol; 2008 Jun 19; 67(6):544-52. PubMed ID: 18397199
    [Abstract] [Full Text] [Related]

  • 17. Antigen identification starting from the genome: a "Reverse Vaccinology" approach applied to MenB.
    Palumbo E, Fiaschi L, Brunelli B, Marchi S, Savino S, Pizza M.
    Methods Mol Biol; 2012 Jun 19; 799():361-403. PubMed ID: 21993656
    [Abstract] [Full Text] [Related]

  • 18. Reverse vaccinology: a genome-based approach for vaccine development.
    Masignani V, Rappuoli R, Pizza M.
    Expert Opin Biol Ther; 2002 Dec 19; 2(8):895-905. PubMed ID: 12517268
    [Abstract] [Full Text] [Related]

  • 19. Vaccinology in the genome era.
    Rinaudo CD, Telford JL, Rappuoli R, Seib KL.
    J Clin Invest; 2009 Sep 19; 119(9):2515-25. PubMed ID: 19729849
    [Abstract] [Full Text] [Related]

  • 20. Identification of new meningococcal serogroup B surface antigens through a systematic analysis of neisserial genomes.
    Pajon R, Yero D, Niebla O, Climent Y, Sardiñas G, García D, Perera Y, Llanes A, Delgado M, Cobas K, Caballero E, Taylor S, Brookes C, Gorringe A.
    Vaccine; 2009 Dec 11; 28(2):532-41. PubMed ID: 19837092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.